Market Research Logo

Colorectal Cancer Therapeutics Market in APAC 2015-2019

About colorectal cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • APAC
  • China
  • Japan
Key vendors
  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Chugai Pharmaceuticals
  • Merck
  • Sanofi
Other prominent vendors
  • Accord Healthcare
  • Advenchen Laboratories
  • Aeterna Zentaris
  • AstraZeneca
  • AVEO Oncology
  • Bavarian Nordic
  • Biothera
  • Boehringer Ingelheim
  • Boston Biomedical
  • Cancer Prevention Pharmaceuticals
  • Celator Pharmaceuticals
  • Daiichi Sankyo
  • Debiopharm
  • Eisai
  • Eli Lilly
  • EpicentRx
  • GlaxoSmithKline
  • Hutchison Medipharma
  • Immodulon Therapeutics
  • Immunomedics
  • MacroGenics
  • Merrimack Pharmaceuticals
  • MolMed
  • Mologen
  • Morphotek
  • Mylan
  • Nektar Therapeutics
  • Oncothyreon
  • Otsuka Pharmaceutical
  • PledPharma
  • Precision Biologics
  • PsiOxus Therapeutics
  • Sun Pharmaceutical
  • Symphogen
  • Taiho
  • Takeda
  • Teva Pharmaceuticals
  • ThromboGenics
  • Xbiotech
  • Yakult Honsha
Key market driver
  • Increase in aging population
  • For a full, detailed list, view our report
Key market challenge
  • Unknown disease etiology
  • For a full, detailed list, view our report
Key market trend
  • Rise in public awareness
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Colorectal Cancer Therapeutics Market in APAC 2015-2019
Technavio recognizes the following companies as the key players in the Colorectal Cancer Therapeutics Market in APAC: Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck and Sanofi
Other Prominent Vendors in the market are: Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, and Yakult Honsha.
Commenting on the report, an analyst from Technavio’s team said: “Biologics are one of the treatment choices for colorectal cancer. These are targeted therapies, which act only on the malignant cells and do not destroy the healthy cells. Biologics that are used for treating colorectal cancer include Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab) and Zaltrap (ziv-Aflibercept). These drugs together accounted for the major share of the market, and the same trend is expected to continue during the forecast period.”
According to the report, many drug makers assist patients financially and enable access to medicines. Patient access programs are designed to fit the needs of individuals with colorectal cancer. For instance, Sanofi’s "Sanofi Patient Connection" program aims to increase access to Zaltrap by providing free prescription medications and financial assistance. Bayer has introduced "Stivarga Reach Program" to provide co-pay assistance to patients. F. Hoffmann-La Roche's "Genentech Access Solutions" is another such program that covers the treatment expenses of patients using Avastin, or provides reimbursement support or co-pay assistance, if the patients fulfill certain criteria.
Further, the report states that the high cost of treatment of colorectal cancer is a major challenge the colorectal cancer therapeutics market in APAC is expected to experience during the forecast period.

Companies Mentioned

Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck, Sanofi, Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, Yakult Honsha.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Product profiles
    • Vectibix
    • Stivarga
    • Erbitux
    • Xeloda
    • Avastin
    • Zaltrap
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • High risk factors
      • Table High risk factors for colorectal cancer
    • Signs and symptoms
      • Table Signs and symptoms of colorectal cancer
    • Pathophysiology
    • Diagnosis
      • Table Diagnostic tests for colorectal cancer
    • Staging
      • Table Staging for colon cancer
      • Table Staging for rectal cancer
    • Biomarker testing
      • Table Types of genes
    • Epidemiology
      • Table Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
      • Table Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
      • Table Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
      • Table Estimated incidence in adult population in APAC 2012
      • Table Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
      • Table Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
    • Treatment
      • Table Treatment options for colorectal cancer
      • Table Types of surgical procedure for colorectal cancer
      • Table Types of radiation therapy for colorectal cancer
      • Table Types of targeted therapy
      • Table Summary of approved cancer drugs for colon cancer
  • Pipeline portfolio
    • Table Pipeline molecules for colorectal cancer
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Colorectal cancer therapeutics market in APAC ($ billions)
    • Colorectal cancer therapeutics market in Japan
      • Table Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
    • Colorectal cancer therapeutics market in China
      • Table Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by based on the type of molecules
    • Table Colorectal cancer therapeutics market in APAC segmented by molecule type
    • Small molecules
    • Biologics
  • Market segmentation by route of administration
    • Table Colorectal cancer therapeutics market in APAC segmented by route of administration
    • Oral
    • Parenteral
  • Market segmentation by lines of chemotherapy
    • First-line chemotherapy
    • Second-line chemotherapy
      • Table Summary of chemotherapy drugs for the treatment of colorectal cancer
      • Table Use of branded targeted therapies in China and Japan 2013
  • Market drivers
    • Table Drivers of colorectal cancer therapeutics market in APAC
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Challenges of colorectal cancer therapeutics market in APAC
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Trends of colorectal cancer therapeutics market in APAC
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
      • Table Amgen: Key takeaways
      • Table Bayer: Key takeaways
      • Table Bristol-Myers Squibb: Key takeaways
      • Table Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
      • Table Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
      • Table Chugai Pharmaceutical: Key takeaways
      • Table Merck: Key takeaways
      • Table Sanofi: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Amgen
      • Table Amgen: Business segmentation by revenue 2014
      • Table Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Amgen: Geographical segmentation by revenue 2014
    • Bayer HealthCare
      • Table Bayer HealthCare: Business segmentation by revenue 2014
      • Table Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Bayer HealthCare: Geographical segmentation by revenue 2014
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Products segmentation by revenue FY2014
      • Table Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
      • Table Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
      • Table Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
    • Chugai Pharmaceutical
      • Table Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
      • Table Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
    • Merck
      • Table Merck: Business segmentation by revenue 2014
      • Table Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Merck: Geographical segmentation by revenue 2014
    • Sanofi
      • Table Sanofi: Business segmentation by revenue 2014
      • Table Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Sanofi: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report